"Cannabis Overhype, FDA-Approved Tripping, And More High-Minded Findings from The Aspen Ideas Festival" - Katie Shapiro
Dennis Charney, MD, the Anne and Joel Ehrenkranz Dean of the Icahn School of Medicine at Mount Sinai and president of academic affairs for the Mount Sinai Health System discussed ketamine while serving as a panelist at the 15th annual Aspen Ideas Festival. According to Dr. Charney, “The first study showing that it was an antidepressant was based on the idea that a neurotransmitter was involved. To our surprise, somewhat, but not completely, we found that low doses produced a very rapid antidepressant effect in some patients within a few hours. And these were patients who had been depressed for many years.”
— Dennis S. Charney, MD, Anne and Joel Ehrenkranz Dean, Icahn School of Medicine at Mount Sinai, President, Academic Affairs, Mount Sinai Health System
